CompletedPhase 2NCT00631800
Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110
Studying Staphylococcal toxemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biosynexus Incorporated
- Principal Investigator
- Leonard Weisman, MDBaylor College of Medicine
- Intervention
- Pagibaximab (formerly BSYX-A110)(drug)
- Enrollment
- 88 target
- Eligibility
- All sexes
- Timeline
- 2003 – 2004
Study locations (1)
- Texas Children's Hospital/Ben Taub Hospital (Baylor College of Medicine), Houston, Texas, United States
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00631800 on ClinicalTrials.govOther trials for Staphylococcal toxemia
Additional recruiting or active studies for the same condition.